Chromane substituted benzimidazole derivatives as acid pump antagonists
This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 , R 7 , R 8 and R 9 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori , dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.
1. A compound of the formula (I):
wherein:
-A-B— is —O—CH 2 —, —S—CH 2 —, —CH 2 —O—, or —CH 2 —S—;
X is an oxygen atom or NH;
R 1 and R 2 are each independently C 1 -C 4 alkyl each being unsubstituted or substituted with 1 to 2 substituents independently selected from hydroxy or C 1 -C 4 alkoxy;
R 3 and R 4 are each independently hydrogen, C 1 -C 4 alkyl, or C 3 -C 7 cycloalkyl, said C 1 -C 4 alkyl and said C 3 -C 7 cycloalkyl being unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, hydroxy, C 1 -C 4 alkoxy, or C 3 -C 7 cycloalkyl; or R 3 and R 4 taken together with the nitrogen atom to which they are attached form a 4 to 6 membered heterocyclic group being unsubstituted or substituted with 1 to 3 substituents selected from hydroxy, C 1 -C 4 alkyl, C 1 -C 4 acyl, or hydroxy-C 1 -C 4 alkyl;
R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, halogen, hydroxy, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy; and
R 9 is hydrogen, hydroxy, or C 1 -C 4 alkoxy; or
a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein:
X is an oxygen atom;
R 3 and R 4 are each independently hydrogen, C 1 -C 4 alkyl, or C 3 -C 7 cycloalkyl, said C 1 -C 4 alkyl and said C 3 -C 7 cycloalkyl being unsubstituted or substituted with 1 to 3 substituents independently selected from hydrogen, hydroxyl, C 1 -C 4 alkoxy, or C 3 -C 7 cycloalkyl; or R 3 and R 4 taken together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, or piperazinyl group, said azetidinyl, pyrrolidinyl group, and piperazinyl groups being unsubstituted or substituted with 1 to 3 substituents selected from hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 acyl, or hydroxyl-C 1 -C 4 alkyl; and
R 6 , R 8 , and R 9 are each hydrogen;
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein:
-A-B— is —CH 2 —O—;
X is oxygen;
R 1 and R 2 are each methyl;
R 3 and R 4 are each methyl; or R 3 and R 4 taken together with the nitrogen atom to which they are attached form an azetidin-1-yl, pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, or 4-acetyl-piperazin-1-yl group;
R 5 and R 7 are independently hydrogen, halogen, or methyl; and
R 6 , R 8 and R 9 are each a hydrogen atom;
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , which is:
4-[(7-Fluoro-3,4-dihydro-2H-chromen-4yl)oxy]-N,N,1,2-tetramethyl-1H-benzimidazole-6-carboxamide;
4-[(5,7-Difluoro-3,4-dihydro-2H-chromen-4-yl)oxy]-N,N,1,2-tetramethyl-1H-benzimidazole-6-carboxamide; or
N,N,1,2-Tetramethyl-4-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)oxy]-1H-benzimidazole-6-carboxamide;
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 1 , and at least one pharmaceutically acceptable carrier.